Caristo Diagnostics
Private Company
Funding information not available
Overview
Caristo Diagnostics is an emerging leader in AI-driven cardiac diagnostics, leveraging over two decades of research to commercialize its CaRi-Heart® platform. The technology extracts novel biomarkers, like the FAI-Score™ for perivascular inflammation, from standard Coronary Computed Tomography Angiography (CCTA) images, providing clinicians with enhanced risk assessment tools beyond traditional measures. With applications in preventive screening, clinical diagnosis, and drug development support, Caristo is positioning itself at the intersection of cardiovascular medicine and artificial intelligence. The company is privately held, has garnered significant scientific recognition, and is focused on expanding clinical adoption through partnerships with imaging centers.
Technology Platform
CaRi-Heart® AI platform that analyzes routine Coronary CT Angiography (CCTA) scans to quantify coronary inflammation (FAI-Score™), characterize plaque (CaRi-Plaque™), and generate an individualized cardiovascular risk score.
Opportunities
Risk Factors
Competitive Landscape
Caristo competes in the AI-powered cardiac imaging analysis space, which includes companies like HeartFlow (FFR-CT) and Cleerly (plaque analysis). Its primary differentiation is the proprietary FAI-Score™, which uniquely quantifies hidden coronary inflammation—a biological risk factor not directly measured by competitors focused on anatomy or physiology.